We are thrilled to announce that Biocytogen will attend the 22nd Annual Meeting of the Oligonucleotide Therapeutics Society from October 11th - 14th, in Denver, Colorado. Come meet our team at booth #33 to grab some swag and learn more about how target-humanized and disease mouse models, together with our gene editing services, can help advance oligonucleotide therapeutics through in vivo target validation, pharmacology, and safety assessment.
What is OTS 2026?
The Oligonucleotide Therapeutics Society (OTS) annual meeting serves as a key forum for industry leaders and researchers dedicated to advancing the future of oligonucleotide-based therapeutics.Through scientific presentations, engaging discussions, and networking opportunities, attendees can exchange insights, foster new collaborations, and explore the latest developments across the field of nucleic acid therapeutics.
Event Overview
Date: October 11th - 14th, 2026
Venue: Colorado Convention Center, 700 14th St, Denver, CO 80202
Booth: 33
Posters
Novel CD98hc-Targeting Antibodies for Blood-Brain Barrier Penetration
A Humanized INHBE Mouse Model Enabling Preclinical Assessment of RNAi Therapeutics
Generation of Humanized ALK7 Mice for Obesity Preclinical Research and Small Nucleic Acid Drug Evaluation
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen has established a dual-engine platform combining a fully human antibody library with an extensive target-humanized mouse model portfolio, enabling a systematic approach to accelerating global drug discovery and development.
Biocytogen has independently developed its proprietary RenMice® (RenMab®/RenLite®/RenNano®/RenTCR™/RenTCR mimic™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, hu-VHH discovery, and TCR mimic antibody discovery, and has established a sub-brand, RenSuper™ Biologics, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2025, more than 350 agreements for therapeutic antibodies and clinical assets—spanning co-development, out-licensing, and transfers—have been
